eXoZymes, Inc.
NASDAQ:EXOZBiotechnology
+$1.06 today
- Market cap
- $51.42M
- Beta
- 2.66
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$1.14
Volume 0.01M
Average 0.01M
EXOZ Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
eXoZymes, Inc.NASDAQ: EXOZ
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns negative
Q1 FY2026 accounts payables was -$1.26K, compared with $147.55K a year earlier. Trailing-twelve-month accounts payables was $162.28K. Over 3 fiscal years it compounded at +37.9% a year.
Context
- Accounts payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near -$1.26K or moves back toward the trailing-twelve-month quarterly average of $40.57K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 311.09K USD
- Year-over-year change
- +40.5%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 311.09K | +40.5% |
| FY2024 | 2024-12-31 | 221.34K | -18.9% |
| FY2023 | 2023-12-31 | 272.89K | +130.3% |
| FY2022 | 2022-12-31 | 118.5K | +155.3% |
| FY2021 | 2021-12-31 | (214.43K) | — |
Accounts Payables vs competitors
How EXOZ compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -48.5% is the 4th highest of 5, against a peer median of +121.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.99M USD | -200.8% | — | — | |
| LTM Mar 2026 | $1.84M USD | +161.8% | — | — | |
| LTM Mar 2026 | CA$1.13M CAD | — | — | — | |
| LTM Mar 2026 | $509K USD | +153.5% | — | — | |
| LTM Mar 2026 | $307K USD | +89.5% | — | 4.1% | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $162.28K USD | -48.5% | +37.9% | — |
| FY2025 | $0 USD | — | — | — | |
| Peer median (excluding EXOZ) | — | +121.5% | — | 4.1% | |
Competitors are the stored peer set for EXOZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.21M) | (1.4M) | (2.04M) | (5.86M) | (9.16M) |
| Depreciation & Amortization | 59.41K | 147.75K | 196.94K | 267.38K | (52.91K) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 198.46K | 216.5K | 281.54K | 1.13M | 1.99M |
| Change in Working Capital | (536.48K) | (190.07K) | 220.31K | (4.02M) | 380.17K |
| Accounts Receivables | (317.07K) | (341.18K) | (72.79K) | 145.04K | 114.72K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (214.43K) | 118.5K | 272.89K | 221.34K | 311.09K |
| Other Working Capital | (4.99K) | 32.61K | 20.21K | (4.38M) | (45.63K) |
| Other Non-Cash Items | (99K) | (35.15K) | 158.73K | (19.4K) | 341.33K |
| Operating Cash Flow | (1.59M) | (1.26M) | (1.18M) | (8.51M) | (6.5M) |
| Capital Expenditures | (422.59K) | (185.98K) | (288.71K) | (396.45K) | (169.92K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 110.33K | 98.77K | (22.46K) | 37.24K | 19.7K |
| Investing Cash Flow | (312.25K) | (87.21K) | (311.17K) | (359.22K) | (150.22K) |
| Debt Repayment | 0 | 0 | 0 | 3.98M | (27.71K) |
| Common Stock Issued | 2.31M | 1.36M | 0 | 14.53M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 1M | 11.82K | 0 |
| Financing Cash Flow | 2.31M | 1.36M | 1M | 18.52M | (27.71K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 413.45K | 10.76K | (492.04K) | 9.65M | (6.68M) |
| Free Cash Flow | (2.01M) | (1.44M) | (1.47M) | (8.9M) | (6.67M) |
eXoZymes, Inc.
NASDAQ:EXOZ
Intrinsic Alpha fair value
Locked
Current Price
$5.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.